A5023676052- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Renal cell carcinoma treatment
- Management of metastatic bone disease
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Cancer and Skin Lesions
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hematological disorders and diagnostics
- Renal and related cancers
- Estrogen and related hormone effects
Policy Analysis (United States)
2016-2019
Acute myeloid leukemia (AML) is associated with high disease burden. This analysis estimated HRU and costs among newly diagnosed AML patients in a US commercially insured population.This was retrospective observational study using the IMS Health PharMetrics Plus Hospital Charge Detail Master databases. Patients included adults who were between January 2007 June 2016 ("study period"). <12 months of continuous enrollment prior to index date excluded, as those whose first diagnosis...
Background Sunitinib and pazopanib are the only two targeted therapies for first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) recommended by United Kingdom's National Institute Health Care Excellence. Pazopanib demonstrated non-inferior efficacy a differentiated safety profile versus sunitinib in phase III COMPARZ trial. The current analysis provides direct comparison cost-effectiveness from perspective Service based on data other sources. Methods A...
The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A + AVD) vs bleomycin, (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness A AVD from a US healthcare payer perspective.The incremental ratio (ICER), defined costs per quality-adjusted life year (QALY) gained, was estimated using non-homogenous semi-Markov cohort model with health states on progression...
Aim: To compare monthly healthcare resource utilization (HRU) and costs among adult patients with multiple myeloma (MM) receiving second or subsequent line of treatment (LOT) carfilzomib pomalidomide as monotherapy in combination dexamethasone. Methods materials: Adult MM who received second/subsequent LOT between 2006 2014 were selected from the MarketScan databases. was determined using Medical/pharmacy claims a published algorithm. For each patient, first defined index LOT. Patients LOT,...
e18330 Background: AML accounts for 25% of acute leukemias in adults worldwide, with an estimated 5-year survival 26% the US. Up-to-date information on clinical and economic burden among US commercially insured patients (pts) is needed to inform reimbursement decisions. Methods: This retrospective study a population used IMS PharMetrics Plus health insurance claims database. Adults ≥1 claim diagnosis (Dx) (ICD-9-CM 205.00, 205.01, or 205.02 ICD-10-CM C92.00, C92.40, C92.50, C92.01, C92.41,...
8060 Background: Disease-related complications and Tx related AEs (collectively “events”), such as anemia, neutropenia, thrombocytopenia, bone loss fractures, kidney disease affect patients with MM. Real-world data on the frequency cost of these “events” is limited. Methods: This was a retrospective observational study using MarketScan database. Adult MM (ICD-9-CM code 203,0x) who initiated between Jan 1, 2006 Dec 31, 2014 were identified. Patients not enrolled continuously for 180 days...
We quantified the frequency and cost of disease-related complications treatment-related AEs (collectively “events”), such as anemia, neutropenia, thrombocytopenia, bone loss fractures, kidney disease that affect patients with MM. This was a retrospective observational study using MarketScan database. Adult MM (ICD-9-CM code 203.0x) who initiated treatment between Jan 1, 2006 Dec 31, 2014 were identified. Patients not enrolled continuously for 180 days pre-diagnosis until 30 after initiation...
8059 Background: The economic burden of MM is substantial. Treatment (Tx) costs for pts have been reported, however, gaps in understanding by line therapy (LOT), service category, and time since Tx initiation remain. Methods: This was a retrospective observational study using the MarketScan database. Pts were adults with (ICD-9-CM code 203.0x) who initiated between Jan 1, ‘06 Dec 31, ‘14. LOT defined receipt new or gap >90 days Tx. prior SCT insufficient continuous enrollment to determine...